Literature DB >> 28447060

Different regimens of perioperative chemotherapy for esophagogastric and gastric adenocarcinoma: does a triplet therapy with taxane generate a survival benefit?

Nicole Samm1, Alexander Novotny1, Helmut Friess1, Daniel Reim1.   

Abstract

Entities:  

Year:  2017        PMID： 28447060      PMCID： PMC5388624          DOI： 10.21037/tgh.2017.03.07

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  16 in total

1.  Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.

Authors:  Christoph Springfeld; Christiane Wiecha; Romy Kunzmann; Ulrike Heger; Wilko Weichert; Rupert Langer; Annika Stange; Susanne Blank; Leila Sisic; Thomas Schmidt; Florian Lordick; Dirk Jäger; Lars Grenacher; Tom Bruckner; Markus W Büchler; Katja Ott
Journal:  Ann Surg Oncol       Date:  2015-05-22       Impact factor: 5.344

2.  [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"].

Authors:  M Moehler; S-E Al-Batran; T Andus; M Anthuber; J Arends; D Arnold; D Aust; P Baier; G Baretton; J Bernhardt; H Boeing; E Böhle; C Bokemeyer; J Bornschein; W Budach; E Burmester; K Caca; W A Diemer; C F Dietrich; M Ebert; A Eickhoff; C Ell; J Fahlke; H Feussner; R Fietkau; W Fischbach; W Fleig; M Flentje; H E Gabbert; P R Galle; M Geissler; I Gockel; U Graeven; L Grenacher; S Gross; J T Hartmann; M Heike; V Heinemann; B Herbst; T Herrmann; S Höcht; R D Hofheinz; H Höfler; T Höhler; A H Hölscher; M Horneber; J Hübner; J R Izbicki; R Jakobs; C Jenssen; S Kanzler; M Keller; R Kiesslich; G Klautke; J Körber; B J Krause; C Kuhn; F Kullmann; H Lang; H Link; F Lordick; K Ludwig; M Lutz; R Mahlberg; P Malfertheiner; S Merkel; H Messmann; H-J Meyer; S Mönig; P Piso; S Pistorius; R Porschen; T Rabenstein; P Reichardt; K Ridwelski; C Röcken; I Roetzer; P Rohr; W Schepp; P M Schlag; R M Schmid; H Schmidberger; W-H Schmiegel; H-J Schmoll; G Schuch; C Schuhmacher; K Schütte; W Schwenk; M Selgrad; A Sendler; J Seraphin; T Seufferlein; M Stahl; H Stein; C Stoll; M Stuschke; A Tannapfel; R Tholen; P Thuss-Patience; K Treml; U Vanhoefer; M Vieth; H Vogelsang; D Wagner; U Wedding; A Weimann; H Wilke; C Wittekind
Journal:  Z Gastroenterol       Date:  2011-04-07       Impact factor: 2.000

Review 3.  Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data.

Authors:  Ulrich Ronellenfitsch; Matthias Schwarzbach; Ralf Hofheinz; Peter Kienle; Meinhard Kieser; Tracy E Slanger; Bryan Burmeister; David Kelsen; Donna Niedzwiecki; Christoph Schuhmacher; Susan Urba; Cornelis van de Velde; Thomas N Walsh; Marc Ychou; Katrin Jensen
Journal:  Eur J Cancer       Date:  2013-06-22       Impact factor: 9.162

4.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Authors:  Marc Ychou; Valérie Boige; Jean-Pierre Pignon; Thierry Conroy; Olivier Bouché; Gilles Lebreton; Muriel Ducourtieux; Laurent Bedenne; Jean-Michel Fabre; Bernard Saint-Aubert; Jean Genève; Philippe Lasser; Philippe Rougier
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

5.  Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.

Authors:  Sylvie Lorenzen; Susanne Blank; Florian Lordick; Jörg-Rüdiger Siewert; Katja Ott
Journal:  Ann Surg Oncol       Date:  2012-03-07       Impact factor: 5.344

6.  Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.

Authors:  Salah-Eddin Al-Batran; Ralf D Hofheinz; Claudia Pauligk; Hans-Georg Kopp; Georg Martin Haag; Kim Barbara Luley; Johannes Meiler; Nils Homann; Sylvie Lorenzen; Harald Schmalenberg; Stephan Probst; Michael Koenigsmann; Matthias Egger; Nicole Prasnikar; Karel Caca; Jörg Trojan; Uwe M Martens; Andreas Block; Wolfgang Fischbach; Rolf Mahlberg; Michael Clemens; Gerald Illerhaus; Katja Zirlik; Dirk M Behringer; Wolff Schmiegel; Michael Pohl; Michael Heike; Ulrich Ronellenfitsch; Martin Schuler; Wolf O Bechstein; Alfred Königsrainer; Timo Gaiser; Peter Schirmacher; Wael Hozaeel; Alexander Reichart; Thorsten O Goetze; Mark Sievert; Elke Jäger; Stefan Mönig; Andrea Tannapfel
Journal:  Lancet Oncol       Date:  2016-10-22       Impact factor: 41.316

7.  Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954.

Authors:  Christoph Schuhmacher; Stephan Gretschel; Florian Lordick; Peter Reichardt; Werner Hohenberger; Claus F Eisenberger; Cornelie Haag; Murielle E Mauer; Baktiar Hasan; John Welch; Katja Ott; Arnulf Hoelscher; Paul M Schneider; Wolf Bechstein; Hans Wilke; Manfred P Lutz; Bernard Nordlinger; Eric Van Cutsem; Jörg R Siewert; Peter M Schlag
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

8.  Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma.

Authors:  J A Ajani; P F Mansfield; N Janjan; J Morris; P W Pisters; P M Lynch; B Feig; R Myerson; R Nivers; D S Cohen; L L Gunderson
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

9.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.

Authors:  Karen Becker; James D Mueller; Christoph Schulmacher; Katja Ott; Ulrich Fink; Raymonde Busch; Knut Böttcher; J Rüdiger Siewert; Heinz Höfler
Journal:  Cancer       Date:  2003-10-01       Impact factor: 6.860

10.  ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).

Authors:  Jens Hoeppner; Florian Lordick; Thomas Brunner; Torben Glatz; Peter Bronsert; Nadine Röthling; Claudia Schmoor; Dietmar Lorenz; Christian Ell; Ulrich T Hopt; J Rüdiger Siewert
Journal:  BMC Cancer       Date:  2016-07-19       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.